Back to Search
Start Over
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
- Source :
-
Nature [Nature] 2022 Jul; Vol. 607 (7917), pp. 119-127. Date of Electronic Publication: 2022 May 16. - Publication Year :
- 2022
-
Abstract
- The recent emergence of SARS-CoV-2 Omicron (B.1.1.529 lineage) variants possessing numerous mutations has raised concerns of decreased effectiveness of current vaccines, therapeutic monoclonal antibodies and antiviral drugs for COVID-19 against these variants <superscript>1,2</superscript> . The original Omicron lineage, BA.1, prevailed in many countries, but more recently, BA.2 has become dominant in at least 68 countries <superscript>3</superscript> . Here we evaluated the replicative ability and pathogenicity of authentic infectious BA.2 isolates in immunocompetent and human ACE2-expressing mice and hamsters. In contrast to recent data with chimeric, recombinant SARS-CoV-2 strains expressing the spike proteins of BA.1 and BA.2 on an ancestral WK-521 backbone <superscript>4</superscript> , we observed similar infectivity and pathogenicity in mice and hamsters for BA.2 and BA.1, and less pathogenicity compared with early SARS-CoV-2 strains. We also observed a marked and significant reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 compared to ancestral and Delta variant strains. In addition, we found that some therapeutic monoclonal antibodies (REGN10987 plus REGN10933, COV2-2196 plus COV2-2130, and S309) and antiviral drugs (molnupiravir, nirmatrelvir and S-217622) can restrict viral infection in the respiratory organs of BA.2-infected hamsters. These findings suggest that the replication and pathogenicity of BA.2 is similar to that of BA.1 in rodents and that several therapeutic monoclonal antibodies and antiviral compounds are effective against Omicron BA.2 variants.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Subjects :
- Animals
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing pharmacology
Antibodies, Neutralizing therapeutic use
Antibodies, Viral pharmacology
Antibodies, Viral therapeutic use
COVID-19 genetics
COVID-19 immunology
COVID-19 virology
Cricetinae
Cytidine analogs & derivatives
Drug Combinations
Hydroxylamines
Indazoles
Lactams
Leucine
Mice
Nitriles
Proline
Spike Glycoprotein, Coronavirus genetics
Triazines
Triazoles
Antiviral Agents pharmacology
Antiviral Agents therapeutic use
SARS-CoV-2 drug effects
SARS-CoV-2 genetics
SARS-CoV-2 pathogenicity
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1476-4687
- Volume :
- 607
- Issue :
- 7917
- Database :
- MEDLINE
- Journal :
- Nature
- Publication Type :
- Academic Journal
- Accession number :
- 35576972
- Full Text :
- https://doi.org/10.1038/s41586-022-04856-1